About SPR Therapeutics
SPR Therapeutics is a private company based in Cleveland, Ohio. It has reported $81,613,514 raised in eight offerings on Form D since October 2011.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 30, 2024 | Feb 5, 2024 | $25,641,473fully sold | 39 | $657K | Equity, Series D-1 Preferred Stock and the underlying Common Stock issuable upon its conversionRule 506(b) | Form D ↗ |
| Aug 20, 2021 | Aug 31, 2021 | $20,000,000of $35.0M target | 1 | $20.0M | Equity, Series D Preferred Stock and the underlying Common Stock issuable upon its conversionRule 506(b) | Form D ↗ |
| Jan 18, 2019 | Jan 30, 2019 | $8,000,000of $20.0M target | 1 | $8.0M | Equity, Series C-1 Preferred Stock and the underlying Common Stock issuable upon its conversionRule 506(b) | Form D ↗ |
| Sep 8, 2017 | Sep 21, 2017 | $15,000,000of $18.8M target | 1 | $15.0M | Equity, Series C Preferred Stock and the underlying Common Stock issuable upon its conversionRule 506(b) | Form D ↗ |
| Apr 30, 2017 | May 5, 2017amended Jul 24, 2017 | $1,111,895of $4.0M target | 12 | $92,658 | Debt, Securities on exercise, 5% Convertible Promissory Note and the underlying senior preferred limited liability membership unitsRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 14, 2015 | Jul 21, 2015amended Oct 7, 2016 | $5,725,881of $6.0M target | 57 | $100K | Debt, Securities on exercise, 5% Convertible Promissory Note and the underlying senior preferred limited liability membership unitsRule 506(b) | Form D/A ↗2 earlier filings |
| Nov 1, 2013 | Oct 31, 2013amended Jun 9, 2014 | $3,931,699of $4.3M target | 28 | $140K | Debt, Securities on exercise, 5% Non-Negotiable Convertible Promissory Notes and the underlying senior preferred limited liability membership unitsRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 1, 2011 | Oct 14, 2011amended Jan 13, 2012 | $2,202,566of $2.5M target | 17 | $129K | Equity06 | Form D/A ↗1 earlier filing |
| Total, eight offerings | $81,613,514 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on SPR Therapeutics's Form D filed Feb 5, 2024.
Earlier filings also listed Mark Stulz (executive officer, last listed Aug 2021), Dave Youngberg (executive officer, last listed Aug 2021), Les Vinney (director, last listed Jan 2019), Marilyn Eisele (vice president of finance and cfo, last listed Oct 2016), Warren Grill (director, last listed Jun 2014), Ralph Della Ratta, Jr. (director, last listed Jun 2014), Patricia Shrader (director, last listed Jun 2014) and Leonard Cosentino (director, last listed Jun 2014).
Sources
- SECSPR Therapeutics, Inc. Form D, filed May 5, 2017
- SECSPR Therapeutics, Inc. Form D/A, filed Feb 2, 2016
- SECSPR Therapeutics, Inc. Form D, filed Jul 21, 2015
- SECSPR Therapeutics, Inc. Form D, filed Oct 31, 2013
- SECSPR Therapeutics, Inc. Form D, filed Oct 14, 2011
- SECSPR Therapeutics, Inc. filing history